Pharma Business - May 2, 2016
Kancera acquires Fractalkine project
Swedish Kancera is to acquire Fractalkine project from Acturum Life Science and the payment for is to be carried in three steps with total of 6 million shares. Due to positive efficacy data in disease models of cancer and pain, Kancera’s Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project. Kancera […]